Flutemetamol F 18 Injection Formulation Comparison

A Multicenter, Phase 2, Open-Label, Randomized, Crossover Comparison of Two Formulations of Flutemetamol F 18 Injection

VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently.

The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.

Study Overview

• Status: Recruiting
• Conditions: Cognitive Dysfunction
• Intervention / Treatment: Drug: GE-287; Drug: Vizamyl

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Paul Sherwin; Phone Number: +1 (609) 5103686; Email: PaulSherwin@gehealthcare.com
• Study Contact Backup: Name: Victoria Haas; Phone Number: 011 33 6 29 86 53 56; Email: ge287201@gehealthcare.com

Study Locations

• United States
  • Florida
    • Aventura, Florida, United States, 33180
      • Recruiting
      • Visionary Investigator Network
    • Merritt Island, Florida, United States, 32952
      • Not yet recruiting
      • Meritt Island Research, LLC dba. Flourish Research
    • Miami, Florida, United States, 33133
      • Recruiting
      • Visionary Investigator Network
    • Miami, Florida, United States, 33176
      • Recruiting
      • Visionary Investigator Network
    • Winter Park, Florida, United States, 32789
      • Recruiting
      • Clinical Site Partners, LLC dba Flourish Research
  • Georgia
    • Gainesville, Georgia, United States, 30501
      • Recruiting
      • Center for Advanced Research & Education LLC dba Flourish Research Gainesville

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 110 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The participant is at least 50 years of age

• The participant (or a legally authorized representative of the participant) has read, signed, and dated an informed consent form (ICF) before any study procedures are performed.

• The participant has been referred for PET imaging with VIZAMYL (flutemetamol F 18 injection) to estimate amyloid β neuritic plaque density for a) evaluation of suspected AD or other causes of cognitive decline and/or b) assessment of participant eligibility for amyloid β-directed therapy for MCI or mild AD as described in the prescribing information of the therapeutic products.

• The participant is able and willing to comply with all study procedures, including lying supine and still in the PET scanner for at least 60 minutes (approximately 2.5 hours total per imaging session, including a break that will be approximately 30 minutes).

• The participant is surgically sterile (has had documented bilateral oophorectomy, bilateral salpingectomy, hysterectomy, bilateral orchidectomy, and/or vasectomy with confirmation of success), postmenopausal (cessation of menses for more than 1 year), or:

  1. If the participant can become pregnant, the participant must:

     • use a highly effective method of contraception from Screening until 30 days after the last dose of flutemetamol F 18 injection,
     • have negative results for serum or urine human chorionic gonadotropin pregnancy tests performed at Screening and on the imaging days (with the result known before each administration), and
     • agree not to harvest or donate eggs until at least 30 days after the last dose of IMP.

  2. If the participant can impregnate another person and has a sexual partner who can become pregnant, the participant and partner must use adequate contraception from Screening until 90 days after the last dose of flutemetamol F 18 injection, and the participant must agree not to harvest or donate sperm from screening through 90 days after the last dose of flutemetamol F 18 injection. If the participant has a sexual partner who is already pregnant, both the participant and the partner must provide written informed consent, and both must agree to abstain from any form of sexual contact for at least 24 hours after flutemetamol F 18 injection administration, and both must agree that once sexual contact resumes, they will use condoms until at least 90 days after administration of the last dose of flutemetamol F 18 injection.

Exclusion Criteria:

• The participant received or plans to receive another IMP within 30 days before signing informed consent until the end of participation in this study.
• The participant has been treated with, or is being treated with, any medicinal product (drug, biologic, or device) believed to be disease-modifying with regard to MCI or AD (such as an anti-amyloid drug), or initiation of such a medical product cannot be postponed until the participant is no longer in this study.
• Including participation in this study, the participant will have received >50 mSv total radiation exposure from medical procedures/tests in the past 12 months.
• The participant has had a procedure (therapeutic or diagnostic) involving a radioisotope and it is not possible to wait at least 4 disintegration half-lives before PET imaging.
• The participant has a measured or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 based on eligibility serum laboratory assessments.
• The participant has a total bilirubin level >1.5X the upper limit of normal (ULN) and/or an aspartate transaminase (AST; serum glutamic-oxaloacetic transaminase [SGOT]) level >3X ULN, and/or an alanine transaminase (ALT, serum glutamic-pyruvic transaminase [SGPT]) level >3X ULN based on eligibility serum laboratory assessments.
• Except for the participant's cognitive impairment, the participant has a history or current evidence of any condition, therapy, or other circumstance that might confound the results of the study, interfere with participation for the full duration of the study, or put the participant at undue risk as judged by the investigator, such that it is not in the best interest of the participant to participate in this study.
• The participant has known/suspected structural abnormalities such as a space-occupying lesion or medical devices such as stents, coils, or electrodes in any key region that may interfere with PET imaging or interpretation/analysis of image data.
• The participant is pregnant, planning to become pregnant, or lactating.
• The participant has known or suspected diabetes.
• The participant is not willing or able to fast completely (except for water and any required medications) for at least 6 hours before administration of IMP until after the post-dose blood samples have been collected on each imaging day.
• The participant has known or suspected allergy or hypersensitivity to either IMP or any of their ingredients (including PS80).
• The participant was previously enrolled in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: GE-287 then Vizamyl	Drug: GE-287; Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously; Drug: Vizamyl; Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
Other: VIZAMYL then GE-287	Drug: GE-287; Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously; Drug: Vizamyl; Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region	90-100 minutes after product administration
Comparison of SUVr in posterior cingulate and precuneus brain region	90-100 minutes after product administration
Comparison of SUVr in lateral temporal brain region	90-100 minutes after product administration
Comparison of SUVr in inferolateral parietal brain region	90-100 minutes after product administration
Comparison of Standard Uptake Value (SUV) in heart	0-60 minutes after product administration
Comparison of SUV in liver	0-60 minutes after product administration
Comparison of SUV in kidneys	0-60 minutes after product administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Comparison of global brain Centiloid values	90-100 minutes after product administration
Comparison of SUV in heart	105-150 minutes after product administration
Comparison of SUV in liver	105-150 minutes after product administration
Comparison of SUV in kidneys	105-150 minutes after product administration
Comparison of blinded visual image interpretations without quantification	90-100 minutes after product administration
Comparison of blinded visual image interpretations with quantification	Time Frame: 90-100 minutes after product administration
Comparison of inter-reader agreement of the blinded visual image interpretations without quantification	90-100 minutes after product administration
Comparison of inter-reader agreement of the blinded visual image interpretations with quantification	90-100 minutes after product administration
Safety: Treatment-emergent adverse event [TEAE] incidence	From pre-administration through 24 hours after product administration
Safety: Changes from baseline in blood hematology	From pre-administration through 180 minutes after product administration
Safety: Change from baseline in serum biochemistry	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in urinalysis	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in blood pressure	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in heart rate	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in respiratory rate	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in temperature	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in general appearance, rated as normal or abnormal by a qualified healthcare provider.	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in examination of the heart, rated as normal or abnormal by a qualified healthcare provider.	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in examination of the lungs, rated as normal or abnormal by a qualified healthcare provider.	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiograms [ECGs] heart rate	from pre-administration through 180 minutes after product administration.
Safety: changes from baseline in 12-lead electrocardiogram [ECG] heart rhythm	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] RR interval	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] PR interval	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QRS interval	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QT interval	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QTc interval	from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] notation of abnormalities	from pre-administration through 180 minutes after product administration

Collaborators and Investigators

• Sponsor: GE Healthcare
• Collaborators: PSI CRO
• Investigators: Study Director: Paul Sherwin, GE Healthcare

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2026
• Primary Completion (Estimated): February 25, 2027
• Study Completion (Estimated): February 25, 2027

Study Registration Dates

• First Submitted: September 21, 2026
• First Submitted That Met QC Criteria: October 7, 2026
• First Posted (Actual): October 14, 2026

Study Record Updates

• Last Update Posted (Actual): November 5, 2026
• Last Update Submitted That Met QC Criteria: November 4, 2026
• Last Verified: November 1, 2026

More Information

Terms related to this study

• Keywords: Alzheimer's disease; Cognitive impairment; PET imaging
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Cognitive Dysfunction; Alzheimer Disease; flutemetamol
• Other Study ID Numbers: GE-287-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

There is not a plan to make IPD available.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No